logo
#

Latest news with #Makary

FDA's new mission to speed drug reviews
FDA's new mission to speed drug reviews

Yahoo

time2 days ago

  • Business
  • Yahoo

FDA's new mission to speed drug reviews

This story was originally published on PharmaVoice. To receive daily news and insights, subscribe to our free daily PharmaVoice newsletter. Between a 20% reduction in workforce in April and the departure of several top officials across departments, the FDA is undergoing a major transition. The job cuts have heightened concerns about potential delays and raised questions about how the federal regulator will keep up with its workload. But Commissioner Dr. Marty Makary has vowed to keep the review wheels churning, and the FDA recently launched its AI tool, Elsa, to help. So far, the overall rate of drug approvals appears to be on track (or better) for the year. And the FDA is looking at other new initiatives to speed up drug reviews. While some of the proposed programs are still short on details, the FDA is expected to release more information about their plans in the coming months. Here's a look at some of the new programs and tools at the FDA aimed at streamlining reviews. The FDA announced plans to launch a new voucher program last month, with the lofty goal of reducing drug review times from as long as a year to as little as a month for select candidates. Dubbed the Commissioner's National Priority Voucher program, the concept replaces the standard review with a team-based approach in which 'a multidisciplinary team of physicians and scientists' will review submitted information in one day. Makary, a surgical oncologist, said the review process will be similar to how teams of doctors make decisions on 'major life-and-death questions for patients' in a 'one-day tumor board-style discussion.' The agency also stated it would issue a 'limited number of vouchers' in the first year, designated for companies 'aligned with U.S. national priorities.' The vouchers operate via four criteria, including if a drug or program addresses a health crisis in the U.S., delivers innovative cures, addresses an unmet public need or increases domestic manufacturing. Drugmakers can be granted a voucher for a specific drug candidate that meets the criteria or as an undesignated voucher that can be used at the company's discretion. Based on the design, drugmakers would use their voucher to submit the chemistry, manufacturing and controls portion of their application for pre-review 60 days before submitting the final application. 'Using a common-sense approach, the national priority review program will allow companies to submit the lion's share of the drug application before a clinical trial is complete so that we can reduce inefficiencies,' Makary said in the statement. The FDA already has voucher programs for drug approvals that incentivize new treatments in certain disease areas, including priority review for rare pediatric disease, tropical disease and medical countermeasures. Unlike the CNPV program, these priority review vouchers can be bought and sold by pharma companies, and they're sometimes worth over $100 million. The CNPV program does not have congressional approval, and the FDA hasn't yet clarified the program's jurisdiction nor how the agency will implement new regulations, according to legal experts. The CNPV program appears to borrow from established voucher programs, allowing drugmakers to pre-submit some information prior to a final new drug application. New vouchers will begin this year. Not all research experts believe the idea will benefit patients at a time when the FDA is operating on a shoe-string staff, and some have questioned the potential dangers of a faster timeline and the potential for the process to become politicized. '[T]he commissioner is forcing the FDA to use its limited resources to rush through reviews of new drugs for unclear reasons,' Dr. Reshma Ramachandran, a member of the board of directors of Doctors for America, said in a statement. 'Corners are likely to be cut.' There's also potential for increased litigation as some drugmakers will experience 'enormous value of a shortened review period' and there's little transparency so far as to how companies will be selected, according to legal experts at Hogan Lovells. Prior to announcing the voucher program, Makary proposed greasing the approval wheels for ultra-rare diseases with a new conditional approval pathway. In his plan, drugs could receive conditional approval based on a 'scientifically plausible mechanism' rather than randomized clinical trial data. Makary announced his idea for the pathway during an interview with Megyn Kelly in April, in line with his policy-from-the-podium approach to regulating, and no further details on the program have since been released. Currently, the FDA grants some drugs accelerated approval on the condition that drugmakers complete confirmatory trials. If these later-stage trials fail, drugs could be pulled from the market. The agency has other mechanisms to speed reviews as well, including fast track and breakthrough therapy designations. So far, based on the few details about the proposed idea, rare disease leaders aren't sure another pathway is needed. 'I would say that the FDA already has sufficient pathways to approve what they need to,' Ultragenyx Pharmaceutical CEO Dr. Emil Kakkis said during a panel at BIO this month in Boston, BioSpace reported. Ultragenyx is a California-based biopharma developing gene therapies for rare and ultra-rare diseases. However, past FDA officials, including Dr. Janet Woodcock, former acting commissioner, and former director of CBER Dr. Peter Marks, have pushed for a revamp of rare disease regulations. Recommended Reading FDA's Elsa AI is here, and the industry has questions Sign in to access your portfolio

FDA requires updated warning about rare heart risk with COVID shots
FDA requires updated warning about rare heart risk with COVID shots

Boston Globe

time5 days ago

  • Health
  • Boston Globe

FDA requires updated warning about rare heart risk with COVID shots

Specifically, the new warning lists the risk of myocarditis as 8 cases per 1 million people who got the 2023-2024 COVID shots between the ages of 6 months and 64 years old. The label also notes that the problem has been most common among males ages 12 to 24. The previous label said the problem mostly occurs in 12- to 17-year-olds. Get Starting Point A guide through the most important stories of the morning, delivered Monday through Friday. Enter Email Sign Up The FDA's labeling change appears to conflict with some prior findings of scientists elsewhere in the U.S. government. Advertisement The Centers for Disease Control and Prevention previously concluded there was no increased risk of myocarditis detected in government vaccine injury databases for COVID-19 shots dating back to 2022. Officials also noted that cases tend to resolve quickly and are less severe than those associated with COVID-19 infection itself, which can also cause myocarditis. The FDA announcement came as new vaccine advisers appointed by Health Secretary Robert F. Kennedy Jr. met to debate the continuing use of COVID-19 vaccines for key groups, including pregnant women. It's the first meeting of the CDC advisory panel since Kennedy abruptly dismissed all 17 members of the group, naming a new panel that includes several members with a history of anti-vaccine statements. Advertisement The FDA's label update is the latest step by officials working under Kennedy to restrict or undercut use of vaccines. FDA Commissioner Marty Makary and a top deputy recently restricted annual COVID-19 shots to seniors and other Americans at higher risk from the virus. They've also suggested seasonal tweaks to match the latest circulating virus strains are new products that require extra testing. Outside experts said the new warning is the wrong approach. 'They are right to suggest that we need to consider myocarditis risks associated with the vaccine, but what they propose is exactly the wrong solution,' said Dr. Robert Morris, a public health specialist at the University of Washington. 'We should be investigating who is prone to myocarditis to see if we can predict and mitigate that risk.' Makary and several other FDA officials gained prominence during the pandemic by suggesting the federal government exaggerated the benefits of COVID-19 boosters and downplayed serious side effects, including myocarditis. Before joining the government, Makary and two of his current FDA deputies wrote a 2022 paper that said mandating booster shots in young people would cause more vaccine-related injuries than prevented hospitalizations from COVID-19 infections. The conclusion contradicted that of many leading vaccine and public health experts at the time, including at the CDC.

FDA requires updated warning about rare heart risk with COVID shots
FDA requires updated warning about rare heart risk with COVID shots

Chicago Tribune

time25-06-2025

  • Health
  • Chicago Tribune

FDA requires updated warning about rare heart risk with COVID shots

WASHINGTON — The Food and Drug Administration said Wednesday it has expanded existing warnings on the two leading COVID-19 vaccines about a rare heart side effect mainly seen in young men. Myocarditis, a type of heart inflammation that is usually mild, emerged as a complication after the first shots became widely available in 2021. Prescribing information from both Pfizer and Moderna already advises doctors about the issue. In April, the FDA sent letters to both drugmakers asking them to update and expand the warnings to add more detail about the problem and to cover a larger group of patients. While the FDA can mandate label changes, the process is often more of a negotiation with companies. Specifically, the new warning lists the risk of myocarditis as 8 cases per 1 million people who got the 2023-2024 COVID shots between the ages of 6 months and 64 years old. The label also notes that the problem has been most common among males ages 12 to 24. The previous label said the problem mostly occurs in 12- to 17-year-olds. The FDA's labeling change appears to conflict with some prior findings of scientists elsewhere in the U.S. government. The Centers for Disease Control and Prevention previously concluded there was no increased risk of myocarditis detected in government vaccine injury databases for COVID-19 shots dating back to 2022. Officials also noted that cases tend to resolve quickly and are less severe than those associated with COVID-19 infection itself, which can also cause myocarditis. The FDA announcement came as new vaccine advisers appointed by Health Secretary Robert F. Kennedy Jr. met to debate the continuing use of COVID-19 vaccines for key groups, including pregnant women. It's the first meeting of the CDC advisory panel since Kennedy abruptly dismissed all 17 members of the group, naming a new panel that includes several members with a history of anti-vaccine statements. The FDA's label update is the latest step by officials working under Kennedy to restrict or undercut use of vaccines. FDA Commissioner Marty Makary and a top deputy recently restricted annual COVID-19 shots to seniors and other Americans at higher risk from the virus. They've also suggested seasonal tweaks to match the latest circulating virus strains are new products that require extra testing. Outside experts said the new warning is the wrong approach. 'They are right to suggest that we need to consider myocarditis risks associated with the vaccine, but what they propose is exactly the wrong solution,' said Dr. Robert Morris, a public health specialist at the University of Washington. 'We should be investigating who is prone to myocarditis to see if we can predict and mitigate that risk.' Makary and several other FDA officials gained prominence during the pandemic by suggesting the federal government exaggerated the benefits of COVID-19 boosters and downplayed serious side effects, including myocarditis. Before joining the government, Makary and two of his current FDA deputies wrote a 2022 paper that said mandating booster shots in young people would cause more vaccine-related injuries than prevented hospitalizations from COVID-19 infections. The conclusion contradicted that of many leading vaccine and public health experts at the time, including at the CDC.

FDA requires updated warning about rare heart risk with COVID shots

time25-06-2025

  • Health

FDA requires updated warning about rare heart risk with COVID shots

WASHINGTON -- WASHINGTON (AP) — The Food and Drug Administration said Wednesday it has expanded existing warnings on the two leading COVID-19 vaccines about a rare heart side effect mainly seen in young men. Myocarditis, a type of heart inflammation that is usually mild, emerged as a complication after the first shots became widely available in 2021. Prescribing information from both Pfizer and Moderna already advises doctors about the issue. In April, the FDA sent letters to both drugmakers asking them to update and expand the warnings to add more detail about the problem and to cover a larger group of patients. While the FDA can mandate label changes, the process is often more of a negotiation with companies. Specifically, the new warning lists the risk of myocarditis as 8 cases per 1 million people who got the 2023-2024 COVID shots between the ages of 6 months and 64 years old. The label also notes that the problem has been most common among males ages 12 to 24. The previous label said the problem mostly occurs in 12- to 17-year-olds. The FDA's labeling change appears to conflict with some prior findings of scientists elsewhere in the U.S. government. The Centers for Disease Control and Prevention previously concluded there was no increased risk of myocarditis detected in government vaccine injury databases for COVID-19 shots dating back to 2022. Officials also noted that cases tend to resolve quickly and are less severe than those associated with COVID-19 infection itself, which can also cause myocarditis. The FDA announcement came as new vaccine advisers appointed by Health Secretary Robert F. Kennedy Jr. met to debate the continuing use of COVID-19 vaccines for key groups, including pregnant women. It's the first meeting of the CDC advisory panel since Kennedy abruptly dismissed all 17 members of the group, naming a new panel that includes several members with a history of anti-vaccine statements. The FDA's label update is the latest step by officials working under Kennedy to restrict or undercut use of vaccines. FDA Commissioner Marty Makary and a top deputy recently restricted annual COVID-19 shots to seniors and other Americans at higher risk from the virus. They've also suggested seasonal tweaks to match the latest circulating virus strains are new products that require extra testing. Outside experts said the new warning is the wrong approach. 'They are right to suggest that we need to consider myocarditis risks associated with the vaccine, but what they propose is exactly the wrong solution,' said Dr. Robert Morris, a public health specialist at the University of Washington. 'We should be investigating who is prone to myocarditis to see if we can predict and mitigate that risk.' Makary and several other FDA officials gained prominence during the pandemic by suggesting the federal government exaggerated the benefits of COVID-19 boosters and downplayed serious side effects, including myocarditis. Before joining the government, Makary and two of his current FDA deputies wrote a 2022 paper that said mandating booster shots in young people would cause more vaccine-related injuries than prevented hospitalizations from COVID-19 infections. The conclusion contradicted that of many leading vaccine and public health experts at the time, including at the CDC. ___

FDA requires updated warning about rare heart risk with COVID shots
FDA requires updated warning about rare heart risk with COVID shots

Yahoo

time25-06-2025

  • Health
  • Yahoo

FDA requires updated warning about rare heart risk with COVID shots

WASHINGTON (AP) — The Food and Drug Administration said Wednesday it has expanded existing warnings on the two leading COVID-19 vaccines about a rare heart side effect mainly seen in young men. Myocarditis, a type of heart inflammation that is usually mild, emerged as a complication after the first shots became widely available in 2021. Prescribing information from both Pfizer and Moderna already advises doctors about the issue. In April, the FDA sent letters to both drugmakers asking them to update and expand the warnings to add more detail about the problem and to cover a larger group of patients. While the FDA can mandate label changes, the process is often more of a negotiation with companies. Specifically, the new warning lists the risk of myocarditis as 8 cases per 1 million people who got the 2023-2024 COVID shots between the ages of 6 months and 64 years old. The label also notes that the problem has been most common among males ages 12 to 24. The previous label said the problem mostly occurs in 12- to 17-year-olds. The FDA's labeling change appears to conflict with some prior findings of scientists elsewhere in the U.S. government. The Centers for Disease Control and Prevention previously concluded there was no increased risk of myocarditis detected in government vaccine injury databases for COVID-19 shots dating back to 2022. Officials also noted that cases tend to resolve quickly and are less severe than those associated with COVID-19 infection itself, which can also cause myocarditis. The FDA announcement came as new vaccine advisers appointed by Health Secretary Robert F. Kennedy Jr. met to debate the continuing use of COVID-19 vaccines for key groups, including pregnant women. It's the first meeting of the CDC advisory panel since Kennedy abruptly dismissed all 17 members of the group, naming a new panel that includes several members with a history of anti-vaccine statements. The FDA's label update is the latest step by officials working under Kennedy to restrict or undercut use of vaccines. FDA Commissioner Marty Makary and a top deputy recently restricted annual COVID-19 shots to seniors and other Americans at higher risk from the virus. They've also suggested seasonal tweaks to match the latest circulating virus strains are new products that require extra testing. Outside experts said the new warning is the wrong approach. 'They are right to suggest that we need to consider myocarditis risks associated with the vaccine, but what they propose is exactly the wrong solution,' said Dr. Robert Morris, a public health specialist at the University of Washington. 'We should be investigating who is prone to myocarditis to see if we can predict and mitigate that risk.' Makary and several other FDA officials gained prominence during the pandemic by suggesting the federal government exaggerated the benefits of COVID-19 boosters and downplayed serious side effects, including myocarditis. Before joining the government, Makary and two of his current FDA deputies wrote a 2022 paper that said mandating booster shots in young people would cause more vaccine-related injuries than prevented hospitalizations from COVID-19 infections. The conclusion contradicted that of many leading vaccine and public health experts at the time, including at the CDC. ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Science and Educational Media Group and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store